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Abstract
Background: To investigate the effects of semaphorin 3A (sema 3A) on cardiac autonomic regulation and
subsequent ventricular arrhythmias (VAs) in post-infarcted hearts.
Method and results: In order to explore the functions of sema 3A in post-infarcted hearts, lentivirus-Sema 3A-shRNA
and negative control vectors were delivered to the peri-infarcted myocardium rats respectively. Meanwhile,
recombinant sema 3A and control (0.9 % NaCl solution) were injected intravenously into infarcted rats to test the
therapeutic potential of sema 3A. Results indicated that levels of sema 3A were higher in post-infarcted hearts
compared with sham rats. However, sema 3A silencing leaded to sympathetic hyperinnervation, increased
myocardial norepinephrine (NE) content and inducible VAs. Conversely, the intravenous administration of sema 3A
to infarcted rats reduced sympathetic nerve sprouting, improved cardiac autonomic regulation, and decreased the
incidence of inducible VAs. However, both infarct size and cardiac function were similar among infarcted hearts.
Conclusions: The upregulation and administration of sema 3A exerted beneficial effects on infarction-induced
cardiac autonomic disorders by increasing cardiac electrical stability and reducing VAs. Sema 3A might be a
potential therapeutic agent for cardiac autonomic abnormalities induced arrhythmias.
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Background
Despite advances in management strategies and patient
education, ventricular arrhythmias (VAs) remain an un-
solved problem, and the identification for patients at a
high risk of sudden cardiac death due to myocardial in-
farction (MI) is still challenging [1, 2]. Increasing studies
have identified that the neural mechanism is correlated
with ventricular arrhythmogenesis [3–7]. Neural control
of the heart is mediated through the parasympathetic
and sympathetic branches of the autonomic nervous sys-
tem, which jointly maintain the normal cardiac function
and electrophysiological stability via innervation balance
and functional confrontation [8]. An imbalanced auto-
nomic nervous system, especially the reduced para-
sympathetic and increased sympathetic tone, has been
commonly found in post-infarcted patients [9]. MI
complicated by sympathovagal imbalance occurs in
some patients, despite of preserved ventricular func-
tion, sufficient exercises, and the use of beta-blockers
[10]. All these findings suggest that cardiac autonomic
disorders complicated MI is associated with an un-
favorable prognosis, therefore, further studies should
be performed.
Cardiac innervation is highly plastic and changed over
time at different stages of cardiovascular disease [3]. MI
induces nerve reinnervations including sympathetic
nerve and cholinergic nerve fibers [11], and infarction-
induced nerve sprouting is mainly sympathetic nerve
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fibers [3, 12]. The increasing sympathetic nerve density
caused by autonomic imbalance is characterized by
increased sympathetic and decreased parasympathetic
activity [8]. Therefore, infarction-induced cardiac auto-
nomic abnormalities might lead to sympathetic over-
activation and subsequent VAs.
Cardiac innervation is sculpted by growth factors dur-
ing infarction. Nerve growth factor (NGF), a chemoat-
tractive factor, plays a key role in sympathetic nerve
sprouting and hyperinnervation [13]. Our previous study
demonstrated that NGF has pleiotropic effects on in-
farcted hearts, and downregulation of NGF does not im-
prove prognosis [14]. However, cardiac reinnervation is
also modulated by chemorepulsive factors such as sema-
phoring 3A (sema 3A). Sema 3A is a secreted protein
that regulates axon/dendrite growth and neuronal mi-
gration. It initiates growth cone collapse, inhibits axonal
outgrowth, and plays crucial roles in neural, cardiac and
peripheral vascular patterning [15]. Sema 3A-deficient
mice exhibit sympathetic hyperinnervation, whereas
sema 3A overexpressing mice lack sympathetic innerv-
ation in developing hearts [16]. Thus, sema 3A is an im-
portant regulatory factor that maintains the balance of
cardiac autonomic nerve during heart development.
The changes in expression and function of semaphor-
ins are correlated with the regenerative failure following
nerve injury [15]. Sema 3A is upregulated during brain
ischemia and spinal cord injury [17, 18]. Overexpression
of sema 3A is also found in MI at the infarcted border
[19]. Meanwhile, sema 3A-deficient mice were with high
risk of sudden death and much more susceptible to VAs,
which is characterized by a high level of sympathetic
nerve density [16]. In addition, upregulating sema 3A by
transfecting the sema 3A gene into the peri-infarcted
zone could reduce sympathetic hyper-reinnervation and
inducible VAs in post-infarcted hearts [19]. Moreover,
variations in the sema 3A gene were identified in unex-
plained cardiac arrest patients with documented ven-
tricular fibrillation [20]. Based on the above analyses,
sema 3A expression plays an important role in cardiac
innervation in heart development and diseased hearts.
The importance of appropriate sema 3A expression in
post-infarcted hearts is highlighted via downregulation
or inhibition of myocardial sema 3A [19]. Therefore,
sema 3A may be a potential therapeutic agent in sympa-
thetic hyperinnervation and subsequent lethal VAs.
In the current study, the effects of sema 3A were in-
vestigated by regulating cardiac sema 3A expression via
the local intramyocardial injection of lentiviral-mediated
sema 3A shRNA and the intravenous injection of recom-
binant sema 3A. Our data revealed that silencing sema
3A augmented sympathetic hyperinnervation, increased
myocardial NE content and inducible VAs. Conversely,
the administration of exogenous sema 3A attenuated
those abnormalities and protected infarcted hearts from
inducible VAs.
Methods
Preparation of sema 3A shRNA lentiviral vector
RNA interference (RNAi) is a post-transcriptional process
that is triggered by the introduction of double-stranded
RNA (dsRNA), which leads to gene silencing in a se-
quence-specific manner. Lentiviral vectors provide a
method of stably introducing exogenous DNA into cells
that are difficult to transfect, allowing for the ectopic ex-
pression or silencing of genes for therapeutic or experi-
mental purposes [21]. A small interference RNA (siRNA)
design tool was used to design the RNA target sequences.
Three selected siRNAs targeting different sites of the sema
3A gene were synthesized, and the corresponding DNA
oligonucleotide (oligo) was cloned into a lentiviral expres-
sion vector. Then, the most effective short hairpin RNA
(shRNA) target was determined by assessing the silencing
efficacy in rat myocardial cells. The lentivirus expressing
the optimal shRNA targeting sema 3A was then propa-
gated and harvested using a virus packaging system (Tele-
bio, Shanghai, China). Next, viral titers were determined
using qPCR [22]. The shRNA construct (GFPi) targeting
the reporter gene eGFP was included as a control.
The lentivirus-sema 3A-shRNA titer was determined
as 2.5 × 1012 vector genomes (vg)/ml, and the lentivirus-
GFP titer was 1 × 1013 vg/ml.
MI model and sema 3A intervention in vivo
All animal experimental procedures were approved by
the Ethics Committee for Animal Studies of Shandong
University, China, and conformed to the Guide for the
Care and Use of Laboratory Animals published by the
United States National Institutes of Health (NIH publi-
cation No. 85–23, revised 1996).
Male Wistar rats (8 weeks old, 280–300 g) were ob-
tained from animal center of Shandong University and
housed under 12 h light/dark cycles in a temperature-
controlled room with free access to food and water. The
left anterior descending (LAD) coronary artery was li-
gated to induce MI, as described previously [14]. Briefly,
rats were anesthetized with 30 mg/kg of 3 % sodium
pentobarbital (intraperitoneal [ip]). The heart was then
exposed using a fourth intracostal left lateral thoracot-
omy after mechanical ventilation. The LAD artery was
ligated permanently at 2 mm from its origin. Coronary
occlusion was confirmed by ST elevation on a surface
electrocardiogram (ECG), as well as regional pallor and
stiff movement of the left ventricle (LV). Meanwhile,
Masson staining was conducted to determine the infarct
size of rats on the day of sacrifice. With respect to clin-
ical importance, only rats with moderate infarct size (30
to 50 %) were enrolled (data was not shown here).
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In order to knockdown sema 3A expression, 80 μl
virus solution including 1.09 × 109 TU/ml lentivirus-
sema 3A-shRNA encoding green fluorescent pro-
tein(GFP) and containing sema 3A shRNA (MI-SiRNA
group, n = 17) was injected intramyocardially at four
sites in the peri-infarcted myocardium (~2 mm around
the infarcted area), as reported previously [14]. The
same amount of virus solution only encoding GFP (MI-
GFP, n = 16) was injected to the rats in control groups.
To investigate the potential therapeutic of sema 3A, the
prepared recombinant sema 3A (Sino Biological Inc,
China; MI-Sema group, n = 11; 1 mg/kg body weight) or
PBS (MI-PBS group, n = 9) was injected intravenously
weekly 3 days after coronary ligation for 4 weeks. An
additional group of rats underwent only LAD ligation
(MI-CON group, n = 9), and a group that underwent
thoracotomy and pericardiotomy (n = 15) were used as
the Sham group. After the incision was closed, the rats
were allowed to recover from the anesthesia in a heated
box, and were then returned to their individual cages.
Hemodynamic measurements and electrophysiological
study
Five weeks after the operation, rats were tracheotomized,
intubated, ventilated mechanically, and monitored after
anesthesia. A pressure-volume catheter (SPR-869, Millar,
Houston, TX, USA) was inserted into the right carotid
artery of rats to measure the mean arterial blood pres-
sure (MAP). Then, the transducer was advanced from
the right carotid artery into the LV to get the pressure-
volume (P-V) data. LabChart Pro software (AD Instru-
ments, Sydney, Australia) was utilized to evaluate LV
end-systolic pressure (LVESP), LV end-diastolic pressure
(LVEDP), the maximal slope of LV systolic pressure in-
crement (dP/dtmax), diastolic pressure decrement (dP/
dtmin), end-diastolic volume (EDV), end-systolic volume
(ESV) and LV ejection fraction (EF).
In addition, an electrophysiological study was per-
formed to evaluate the susceptibility of rats in a stable
condition to VAs. The protocol used for programmed
electrical stimulation (PES) was performed as reported
previously [4, 23]. After monitoring the surface ECG, a
second thoracotomy was carried out. PES was performed
via a specially modified electrode with a needle-point
inserted into the epicardial surface of the infarcted
border (2 mm deep). After measuring the pacing thresh-
old, standard PES protocols were performed as follows:
burst (cycle length 100 ms, S0), single (S1), double (S2),
and triple (S3) extrastimuli. The coupling interval of the
last extra stimulus was decreased from 80 ms to the
value of ventricular effective refractory period with 2-ms
steps. The experimental protocols were completed
within 10 min. Ventricular tachyarrhythmias, including
ventricular tachycardia and ventricular fibrillation, were
considered non-sustained when they lasted < 15 beats
and sustained when they lasted > 15 beats. Ventricular
arrhythmia scores were determined by the inducibility
quotient of ventricular tachyarrhythmias as follows: 0,
non-inducible; 1, non-sustained tachyarrhythmias in-
duced with three extrastimuli; 2, sustained tachyarrhyth-
mias induced with three extrastimuli; 3, non-sustained
tachyarrhythmias induced with two extrastimuli; 4, sus-
tained tachyarrhythmias induced with two extrastimuli;
5, non-sustained tachyarrhythmias induced with one
extrastimulus; 6, sustained tachyarrhythmias induced
with one extrastimulus; 7, tachyarrhythmias induced
during a train of eight stimuli (8 × S1) at a basic
cycle length of 100 ms; and 8, heart stopped before
PES. The highest score was used when multiple
forms of tachyarrhythmias occurred in one heart
[23]. Finally, heart tissues were sampled according to
corresponding experimental techniques.
Immunohistochemistry and Masson’s trichrome staining
Immunohistochemistry and Masson’s trichrome staining
were performed as described previously [14]. Briefly, par-
affin sections were deparaffinized, rehydrated, incubated
and then treated with citric acid buffer. After incubated
with serum-free protein blocking buffer (ZSGB-BIO,
Beijing, China), sections were incubated with rabbit anti-
TH (tyrosine hydroxylase, 1:100; Millipore, Billerica, MA,
USA), rinsed and incubated in horseradish peroxidase-
(HRP-) conjugated secondary antibodies, and then coun-
terstained with hematoxylin. Finally, the sections were
mounted and examined using a microscopy. The density
is expressed as the ratio of labeled nerve fiber area to total
area, while papillary muscles were excluded from the
study because a variable sympathetic innervation has been
reported [24].
In addition, samples from the apex, mid-LV, and base
were paraffin-embedded, sectioned and stained with
Masson’s trichrome stain. The infarct size percentage
was calculated as fibrosis area/total LV area × 100. All
images were analyzed with ImageJ software ImagePro
Plus 5.0 (Media Cybernetics, Bethesda, MD).
Western blotting
Proteins were extracted from cardiac issues prepared
from the infarcted border using a Nuclear and Cytoplas-
mic Protein Extraction Kit (Beyotime, Haimen, China).
Protein concentrations were quantified using a bicincho-
ninic acid (BCA) protein assay kit (Beyotime). From
each extract, 40 μg proteins was separated using 10 %
SDS-PAGE, and then transferred to polyvinylidene fluor-
ide (PVDF) membranes (Bio-Rad, Hercules, CA, USA).
Membranes were blocked in 5 % non-fat milk, followed
by incubated with anti-TH (1:1000), anti-CHAT (choline
acetyltransferase, 1:1500; Millipore, Billerica, MA, USA),
Hu et al. BMC Cardiovascular Disorders  (2016) 16:16 Page 3 of 10
anti-NGF (1:1500, Epitomics, Burlingame, CA, USA), anti-
sema 3A (1:1000, Abcam, Cambridge, England) or anti-
GAPDH (glyceraldehyde-3-phosphate dehydrogenase,
1:3000; CoWin Bioscience, Beijing, China) antibodies. After
washed with PBS, the membranes were incubated with
the corresponding secondary antibodies, and images were
developed using an enhanced chemiluminescence detec-
tion kit. Immunoreactive bands were visualized using a
FluroChem E Imager (ProteinSimple, Santa Clara, CA,
USA). The expression levels of the target proteins were
measured and normalized to GAPDH.
Real-time quantitative PCR
Total RNA was isolated from samples at infarcted
border zone (3 mm zone adjacent to the infarcted area),
and the mRNA expression levels of TH, CHAT, NGF,
and sema 3A were assessed by real-time quantitative
RT-PCR using a PrimeScript RT reagent kit (TaKaRa,
Dalian, China) in a Mastercycler EP realplex detection
system (Roche, Indianapolis, IN, USA) as reported previ-
ously. For each sample, GAPDH and the target genes
were amplified in duplicate in separate tubes. Each
measurement was performed in triplicate. Gene expres-
sion was analyzed using the 2-ΔΔCT method described by
Livak and Schmittgen [25]. The primers for each gene
used in this study were as follows:
NGF forward 5‘-TCGCTCACTCCACTATCCACTA-3’,
and reverse 5‘-GACTCAACAGGGCAAGCATAC-3’; sema
3A forward 5‘-GAGTGATGTAAGAAGGGTGTTCC-3’,
and reverse 5‘-CAAGTTCCTGGTCGTGGATAAG-3’; TH
forward 5‘-GGCTTCTCTGACCAGGTGTATC-3’, and re-
verse 5‘-TAGCAATCTCTTCCGCTGTGTA-3’; CHAT
forward 5‘- AGCCCCTCTGTATGAAGCAAT–3’, and re-
verse GGACGCCATTTTGACTATCTTT-3’; GAPDH
forward 5‘-ACAGCAACAGGGTGGTGGAC-3’, and re-
verse 5‘-TTTGAGGGTGCAGCGAACTT-3’.
High performance liquid chromatography (HPLC)
According to previously reported studies [26, 27], we
measured norepinephrine(NE) and acetylcholine (ACh)
levels in heart tissue isolated from the infarcted border
using HPLC with electrochemical detection. Briefly, fresh
heart samples (50 mg) were transferred immediately into
perchloric acid containing isopropylhomocholine as an in-
ternal control. They were then homogenized, centrifuged,
and filtered to obtain an HPLC samples. HPLC was then
used to quantify Ach and NE levels.
Statistical analyses
Data are presented as means ± standard deviations (SD).
Independent t-tests were used to compare values between
two groups. ANOVA followed by Tukey’s test was used to
compare differences between more than two groups. Ana-
lyses were performed using SPSS 17.0 software (SPSS Inc.,
Chicago, IL, USA). A value of P < 0.05 was considered
statistically significant.
Results
Sema 3A knockdown using recombinant lentivirus vectors
in vitro and in vivo
The mRNA and protein expression of sema 3A were
assessed in a rat myocardial cell line to identify the knock-
down efficacy of different siRNAs (Fig. 1). The results sug-
gested that the sequence 5‘-GGTGTTCCTTGGTCCA
TATGC-3’ resulted in the most effective knockdown of
sema 3A in vitro. Therefore, this sequence was packaged
and used for in vivo studies. Both mRNA and protein
levels of sema 3A were higher in the MI-CON group than
those in the Sham group at 1, 2, and 5 weeks after infarc-
tion (P < 0.01, Fig. 2). In addition, compared with the MI-
GFP group, the expression of sema 3A was significantly
lower in the MI-SiRNA group (P < 0.01, Fig. 2).
Effects of Sema 3A on inducible VAs, infarct size, and
hemodynamics in post-infarcted hearts
There was no significant difference in the infarct size
and hemodynamic data among the MI groups (Table 1).
To assess the incidence of potential VAs, we designed an
electrophysiological study to assess the cardiac electrical
stability. Ventricular tachyarrhythmias were inducible by
programmed stimulation in infarcted rats as showed in
Fig. 3a–c. The percentage of inducible ventricular
arrhythmia is negatively correlated with the expression
level of sema 3A (Fig. 3d). The arrhythmia scores for
sham rats were nearly 0 (Fig. 3e). Silencing sema 3A sig-
nificantly increased the inducibility of ventricular tachy-
arrhythmia in infarcted rats compared with counterpart
vehicle treatment; in contrast, sema 3A administration
significantly decreased the inducibility of ventricular
tachyarrhythmia (both p < 0.05) (Fig. 3e). Therefore, ex-
ogenous sema 3A could stabilize cardiac electrical activ-
ity and reduce the incidence of VAs.
Effects of silencing Sema 3A on sympathetic
hyperinnervation, ratio of TH/CHAT and myocardial NE
level
As shown in Figs. 4 and 5 and Table 2, MI caused nerve
sprouting and sympathetic neural remodeling in the MI-
CON and MI-GFP groups, and the TH-positive nerve
densities were increased at the infarcted border. Mean-
while, the protein expression of TH and CHAT was
higher in the MI-CON and MI-GFP groups. However, a
higher TH-positive nerve density was detected in the
MI-SiRNA group compared with the MI-GFP group
(Fig. 4 and Table 2). Sema 3A silencing increased mRNA
and protein levels of TH at the infarcted border (Table 2)
but did not affected CHAT expression. Thus, the ra-
tio of TH/CHAT protein was higher in MI-SiRNA
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group compared with the MI-CON and MI-GFP groups
(Table 2).
Myocardial NE and ACh were measured to evaluate
autonomic nerve function. Both myocardial NE and
ACh levels at the infarcted border were higher in the
MI-CON and MI-GFP groups compared with the sham
group. After sema 3A silencing, myocardial NE level was
higher than that in the MI-GFP group. However, there
were no significant differences of ACh levels between
the MI-SiRNA and MI-GFP groups (Table 2).
Fig. 1 The effectiveness of sema 3A-siRNA as determined by reduced protein and mRNA levels in vitro. a RT-PCR demonstrating sema 3A mRNA
expression in rat myocardial cells transfected with sema 3A-shRNA 1 (SiRNA-1), 2 (SiRNA-2), and 3 (SiRNA-3), or PBS-control (Control) (*P < 0.01 vs.
SiRNA-1). b, c Western blotting showing the expression of sema 3A in rat myocardial cells in various groups. (*P < 0.01 vs. SiRNA-1). d Image
showing the effect of shRNA-3 in cultured rat myocardial cells using fluorescence microscopy
Fig. 2 The time-course expression of sema 3A in myocardial infarction (MI) models after lentivirus-sema 3A-shRNA treatment. a, b Western
blotting was conducted to detect the effects of lentivirus-sema 3A-shRNA on the protein level of sema 3A (95 KDa) at various time points (1, 2,
and 5 weeks). The relative expression of sema 3A was normalized to GAPDH (36 KDa). c Relative mRNA expression of sema 3A was detected using
real-time quantitative RT-PCR. The relative gene expression of sema 3A was analyzed using the 2-ΔΔCT method. Data are presented as means ± SD.
*P < 0.05 vs. sham group. †P < 0.05 vs. MI-siRNA group
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Table 1 Hemodynamic data based on pressure-volume and infarct size 5 weeks after MI
Sham MI-CON MI-GFP MI-SiRNA MI-Sema MI-PBS
n 9 9 10 11 11 9
Infarct size (%) 42.7 ± 5.1 42.9 ± 4.7 44.3 ± 5.2 43.5 ± 4.2** 41.3 ± 4.9
HR (beats/min) 419.2 ± 19.1 424.5 ± 17.2* 421.4 ± 21.2 427.3 ± 19.2 419.2 ± 19.1** 420.1 ± 19.2
MAP (mmHg) 109.2 ± 3.7 92.4 ± 6.4* 93.2 ± 7.9 89.7 ± 8.1 92.7 ± 7.3** 93.7 ± 7.7
LVDSP (mmHg) 2.92 ± 0.97 6.3 ± 1.2* 5.8 ± 1.4 5.7 ± 1.6 6.1 ± 1.9** 5.9 ± 1.4
LVESP (mmHg) 119.3 ± 9.2 91.2 ± 5.9* 89.2 ± 6.1 90.2 ± 7.1** 88.3 ± 6.8** 91.4 ± 7.1
EDV (μl) 309.4 ± 21.3 483.2 ± 33.7* 467.6 ± 41.4 475.1 ± 48.1** 471.3 ± 47.4** 469.3 ± 45.3
ESV (μl) 106.1 ± 114 293.4 ± 19.4* 289.2 ± 23.1 291.2 ± 24.1** 289.4 ± 27.3** 285.7 ± 24.2**
EF (%) 61.2 ± 1.7 34.7 ± 0.7* 35.3 ± 06 34.9 ± 0.8 34.2 ± 0.9** 33.9 ± 1.0
dP/dtmax (mmHg/s) 5517.4 ± 129 3696.2 ± 90.2* 3712.7 ± 91.8 3637.4 ± 83.7 3707.2 ± 73.1** 3684.3 ± 80.5
dP/dtmin (mmHg/s) −3989.1 ± 147 −2379.4 ± 77.5* −2394.7 ± 90.3 −2427.4 ± 84.3 −2312.5 ± 74.9** −2419.4 ± 94.2
Values are presented as means ± SD. HR, heart rate; MAP mean arterial pressure, LVEDP LV end-diastolic pressure, LVESP LV end-systolic pressure, EDV end-diastolic
volume, ESV end-systolic volume, EF ejection fraction, dP/dtmax and dP/dtmin maximal slope of the systolic pressure increment and the diastolic pressure decre-
ment, respectively.* P < 0.05 vs. sham group, ** P > 0.05 among various MI groups
Fig. 3 Various ventricular arrhythmias induced by programmed electrical stimulation in infarcted rats. a Eight basic stimuli (S0) at cycle lengths of
100 ms and two extra stimuli (S1 and S2) induced monomorphic ventricular tachycardia (VT). b Eight basic stimuli (S0) and two extra stimuli
(S1 and S2) induced polymorphic ventricular tachycardia. c Seven basic stimuli (S0) induced ventricular fibrillation (Vf). d The percentage of
inducible total ventricular arrhythmias/ stimulation times.* P < 0.05 vs. MI GFP group; **P < 0.01 vs. MI-PBS group; †P > 0.05 vs. MI-CON group.
e Inducibility quotient of induced ventricular arrhythmias 5 weeks after infarction. * P < 0.01 vs. MI GFP group; **P < 0.01 vs. MI-PBS group,
†P > 0.05 vs. MI-CON group
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Sema 3A administration promoted cardiac innervation
and function
To explore the potential therapeutic effects of sema 3A
in infarcted hearts, recombinant sema 3A was injected
as described previously [28]. Data revealed that intraven-
ously administrated sema 3A dramatically decreased the
sympathetic nerve density nerve fibers, accompanied by
decreased protein and mRNA levels of TH and de-
creased TH/CHAT ratio (Fig. 3 and Table 2). In
addition, as is shown in Fig. 5, knockdown or overex-
pression of sema 3A in infarcted rats did not seem to
affect CHAT level, supported by the fact that neural re-
modeling post-infarction is mostly characterized by
sympathetic hyperinnervation. Therefore, the alleviated
TH/CHAT ratio by sema 3A is mainly through the
downregulation of TH.
Myocardial NE levels were lower in the MI-Sema
group compared with the MI-PBS group. However, there
was no significant difference in myocardial ACh levels
between the MI-PBS and MI-Sema groups (all P > 0.05).
Moreover, both the mRNA and protein levels of NGF
were comparable among the MI groups (Fig. 5), which
suggested that sema 3A affected the post-infarcted car-
diac autonomic nerve independent of NGF.
Discussion
Increased sympathetic tone and densities are important
in the generation of VAs and subsequently sudden car-
diac death. MI results in abnormal cardiac autonomic
regulation in terms of both neural distribution and func-
tion. The MI-complicated abnormalities might cause un-
favorable prognosis such as lethal VAs and sudden
cardiac death [8, 29, 30]. The current study revealed that
silencing sema 3A enhanced the abnormalities of cardiac
autonomic regulation and increased the incidence of in-
ducible VAs in post-infarcted hearts. Moreover, overex-
pression of sema 3A reduced sympathetic nerve
sprouting, ameliorated cardiac autonomic imbalance,
and decreased the incidence of inducible VAs. Infarct
size and cardiac function were similar among the MI
groups. Therefore, sema 3A has therapeutic potential for
post-infarcted cardiac autonomic abnormalities.
Fig. 4 Histological study of cardiac nerve fibers at the infarcted border zone in sham-operated and infarcted hearts. Immunohistochemistry staining
for tyrosine hydroxylase (magnification × 200): (a), MI-CON (b), MI-SiRNA (c), MI-GFP (d), MI-PBS (e), and MI-Sema (f) groups
Fig. 5 The effects of sema 3A on the expression levels of NGF, TH and CHAT. a Representative western blots showing sema 3A (95 KDa), NGF (27
KDa), TH (58 KDa), CHAT (72KDa), and GAPDH (36 KDa) expression in various groups. b MI resulted in the increase of NGF mRNA and protein
expression in the MI-CON group compared with the sham group (*P < 0.05). Both were similar in various MI groups. **P > 0.05 vs. MI-GFP group;
†P > 0.05 vs. MI-PBS group
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Normal cardiac function and rhythm are maintained
by balancing the actions of sympathetic and parasympa-
thetic inputs to the heart [31]. The electrical and con-
tractile activities of myocardium are modulated by the
release of NE from sympathetic neurons and the secre-
tion of ACh from parasympathetic neurons. However,
the normal balance between cardiac autonomic neurons
is disrupted by MI, which leads to increased sympathetic
and decreased parasympathetic transmission in the heart
[32]. Neurotrophins, such as sema 3A and NGF, regulate
axonal growth, synaptic plasticity, survival, differentiation,
myelination, and nerve patterning during both cardiac de-
velopment and diseased pathologies [13, 16, 33–35].
Sema 3A is a neural chemorepellent as an axon guid-
ance molecule that plays important roles in the develop-
ment of the nervous system and axon growth [15].
Appropriate sema 3A expression in heart is required for
sympathetic innervation patterning. Both sema 3A silen-
cing and sema 3A overexpressing exhibited disrupted in-
nervation patterning in mice [16]. In post-infarcted
hearts, the lentivirus-mediated overexpression of sema
3A in the infarcted zone alleviated sympathetic hyper-
reinnervation [19]. The increased expression of sema 3A
in heart failure might partially account for the cardiac
sympathetic denervation [36]. Consistent with the previ-
ous study [19], sema 3A expression was increased in the
myocardium of MI rats. Besides, the mRNA and protein
expression levels of TH were significantly higher in sema
3A-silenced rats compared with the MI-GFP and MI-
CON groups. These results suggest that the upregulation
of sema 3A might partially suppress sympathetic nerve
sprouting and subsequently decrease sympathetic nerve
expression.
Previous studies revealed an increased expression of
CHAT mRNA and protein in MI [11]. Nevertheless, in
the current study, the ratio of TH/CHAT protein was
higher in MI-SiRNA group than that in MI-CON and
MI-GFP groups. Consistently, in the MI-SiRNA group,
higher levels of NE were detected accompanied with a
higher arrhythmic score and an increased incidence of
inducible VAs. Previous studies revealed that sympa-
thetic hyperinnervation and activation were correlated
with a high incidence of lethal VAs and sudden cardiac
death in post-infarcted hearts [5, 7, 8, 30]. In addition,
pro-arrhythmia effects were reported in sema 3A-related
neural remodeling animals [16, 19]. Recently, Nakano et
al. demonstrated that a non-synonymous polymorphism
in sema 3A was correlated with human unexplained car-
diac arrest and ventricular fibrillation with inappropriate
innervation patterning [20]. Taken together, these data
suggest that sema 3A might play a critical role in main-
taining cardiac electrical stability by preserving normal
cardiac innervation in diseased hearts.
In damaged neural tissues, upregulated sema 3A could
hinder neuroregeneration and remyelination [15]. Over-
expression of sema 3A in the infarcted border via local
myocardial gene transduction reduces sympathetic hy-
perinnervation and inducible VAs in post-infarcted
hearts [19]. In our study, sema 3A expression was in-
creased in vivo by intravenously injecting recombinant
Table 2 Effects of sema 3A on autonomic abnormalities 5 weeks after infarction
Sham MI-CON MI-GFP MI-SiRNA MI-Sema MI-PBS
1-RT-PCR (target mRNA /GAPDH) TH 1 2.93 ± 0.21 2.87 ± 0.18 3.82 ± 0.34* 1.84 ± 0.14** 3.12 ± 0.23***
CHAT 1 1.66 ± 0.14 1.71 ± 0.17 1.67 ± 0.16 1.61 ± 0.14**** 1.72 ± 0.17
2- IHC (um2/mm2) TH-positive 1281 ± 75.1 3589 ± 278.1 3539 ± 176 4707 ± 193.2* 2330 ± 162.4** 3564 ± 118.9***
Sema 3A protein 0.14 ± 0.02 0.35 ± 0.03 0.33 ± 0.025 0.167 ± 0.02* 0.44 ± 0.03** 0.31 ± 0.02***
3- WB (target protein/GAPDH) TH protein 0.19 ± 0.03 0.45 ± 0.035 0.47 ± 0.029 0.67 ± 0.027* 0.35 ± 0.014** 0.48 ± 0.03***
CHAT protein 0.085 ± 0.087 0.174 ± 0.013 0.174 ± 0.01 0.173 ± 0.011 0.167 ± 0.011** 0.179 ± 0.09
TH/CHAT 2.18 ± 0.25 2.63 ± 0.26 2.67 ± 0.19 3.77 ± 0.20* 2.66 ± 0.18** 2.10 ± 0.10***
4- HPLC (pmol/mg) NE 2.1 ± 0.12 4.3 ± 0.29 4.1 ± 0.31 5.1 ± 0.27* 2.9 ± 0.26** 3.9 ± 0.27***
ACh 2.9 ± 0.26 3.9 ± 0.23 3.8 ± 0.27 3.5 ± 0.24 3.6 ± 0.28**** 3.8 ± 0.27
(1) RT-PCR was used to assess the mRNA expression of TH, and CHAT in various groups. Sema 3A silencing increased the expression of GAP 43 and TH compared
with the MI-GFP group (P < 0.05). However, the administration of sema 3A reduced the expression in TH compared with the MI-PBS group (P < 0.05). CHAT mRNA
expression was comparable between various MI groups (P > 0.05). (2) Immunohistochemistry results revealed that the density of TH- and GAP 43- positive nerve
fibers were higher in sema 3A-silenced infarcted-hearts compared with the MI-GFP group (both P < 0.05). Recombinant sema 3A reduced the number of TH- and
GAP 43- positive nerve fibers compared with the MI-PBS group (both P < 0.01). There was no difference in the density of TH- nerve fibers among the MI-CON,
MI-GFP, and MI-PBS groups (all P > 0.05). (3) Western blot (WB) showing increased protein expression of TH and CHAT in the MI-CON group compared with the
sham group (P < 0.05). Sema 3A silencing increased the expression of TH protein, whereas sema 3A administration reduced TH protein expression. CHAT protein
expression was comparable among the various MI groups. However, the ratio of TH/CHAT protein expression was increased in the MI-SiRNA group compared with
the MI-GFP group (P < 0.05). The ratio was lower in the MI-Sema group compared with the MI-PBS group (P = 0.021), but there was no significant difference between
the MI-Sema and sham groups (P = 0.34). (4) HPLC was used to assess local sympathetic and parasympathetic activity. MI resulted in increased myocardial NE
and Ach levels in the MI-CON group compared with the sham group (both P < 0.05). NE content was increased in the MI-SiRNA group compared with the
MI-GFP group (P = 0.007). In addition, NE content was reduced in the MI-Sema group compared with the MI-PBS group (P = 0.024). However, myocardial Ach
levels were similar in the various infarcted groups (P > 0.05). * P < 0.05 vs. MI-GFP group, **P < 0.05 vs. MI-SiRNA group, ***P < 0.05 vs. MI-sema group, ****P > 0.05
among various MI groups
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sema 3A. Five weeks after infarction, TH-positive nerve
fibers, as well as its mRNA and protein levels, were all
decreased in the MI-Sema group. However, there was no
significant difference in the expression of CHAT and
myocardial ACh levels between the MI-control and MI-
Sema groups. The protein ratio of TH/CHAT was re-
duced to relatively normal levels, similar to that in the
sham group (P = 0.34), via downregulating TH expres-
sion by sema 3A. The incidence of inducible VAs and
myocardial NE levels were also lower in the MI-Sema
group compared with the MI-CON and MI-PBS groups.
Sympathetic overactivity complicated MI leads to an in-
crease of NE concentration which encourages the early
depolarization (EAD) and delayed afterdepolarization
(DAD) by affecting influx and repolarization potassium
current, and then trigger arrhythmia [37]. Moreover, NE
may cause focal vasoconstriction and myocardial ische-
mia which facilitates- arrhythmogenesis [38]. Sema 3A
suppresses the expressions and functions of myocardial
transient outward current (Ito) and inward rectifier
current (IK1) channels. Sema 3A ameliorates electrical
remodeling in post-infarcted heart which is partly related
with the inhibition of sympathetic nerve sprouting [39].
All these studies indicate that sympathetic innervation is
also closely related to electrical homogeneity. Consist-
ently, overexpression of sema 3A decreased sympathetic
nerve sprouting activity and nerve density, improved
TH/CHAT ratio and further reduced myocardial NE
level according to our results. These effects may contrib-
ute to the increased cardiac electrical stability, resulting
in reduced inducible VAs.
Infarct size and cardiac dysfunction are predictive fac-
tors of VAs in post-infarcted-hearts [40]. This current
study revealed that these two factors were similar among
MI groups, suggesting that sema 3A affected cardiac
rhythm independent of infarct size and cardiac function
in post-infarcted hearts. Sema 3A inhibits NGF-induced
nociceptive afferent sprouting in spinal cords of adult
rats [41]. However, both sema 3A silencing and overex-
pression did not alter the up-regulated NGF mRNA and
protein in post-infarcted hearts. Cardiac innervation pat-
terning is strictly controlled by the balance between NGF
and sema 3A [16]. Treatment with exogenous sema 3A
might alleviate the infarction-induced imbalance between
NGF and sema 3A and suppress nerve sprouting, espe-
cially the sympathetic nerve. Furthermore, both sema 3A
deficiency and supplementation did not alter the expres-
sion of CHAT protein and mRNA levels. Therefore, sema
3A treatment improved cardiac autonomic abnormalities
mainly by affecting the sympathetic nerve.
Limitations
Coronary arteriosclerosis is the main cause of clinical
MI in patients. In the current study, we ligated the left
anterior descending coronary artery and created a MI
model that was different from the clinical setting. More-
over, the different infarct sizes (small or large) and sites
(anterior, inferior, or posterior wall) might partly affect
the expression of neurotrophic factors and ventricular
arrhythmogenesis. However, autonomic nerve function
can be affected by animal emotions and surroundings.
Clinically, heart rate variability (HBV), baroreflex sensi-
tivity (BRS), and heart rate recovery (HRR) are used fre-
quently to evaluate autonomic nerve function [42].
Myocaridial NE and ACh levels are also measured to as-
sess nerve function. Nevertheless, additional studies are
necessary to explore the mechanisms of effects of sema
3A on post-infarcted neural remodeling and its relation-
ship with cardiac autonomic function. Such studies will
provide further insights into sema 3A as a therapeutic
target for autonomic abnormalities complicated cardiac
electrical instability.
Conclusion
MI results in nerve injury and upregulation of the neur-
onal regulator sema 3A. Endogenous sema 3A partially
inhibits nerve sprouting, whereas the downregulation of
sema 3A aggravates the cardiac autonomic disorders and
increases the potential of lethal VAs in post-infarcted
hearts. Intravenous injection of sema 3A improves the
autonomic abnormalities at the levels of both innerv-
ation and nerve function, mainly sympathetic nerve, and
subsequently increases cardiac electrical stability and re-
duces inducible VAs. Therefore, sema 3A might be a
therapeutic target for autonomic disorders induced VAs
in post-infarcted hearts.
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